Sign up to save your podcasts
Or
Share Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
View all episodes
By cancerGRACE - H. Jack West, MD
5
11 ratings
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
More shows like GRACEcast Lung Cancer Video
View all
GRACEcast Head and Neck Cancer Audio
2 Listeners
GRACEcast Radiation Oncology Audio
0 Listeners
GRACEcast Radiation Oncology Video
0 Listeners
GRACEcast Pancreatic Cancer Audio
0 Listeners
GRACEcast Pancreatic Cancer Video
1 Listeners
GRACEcast Cancer 101 Audio
0 Listeners
GRACEcast Bladder Cancer Video
0 Listeners
GRACEcast Head and Neck Cancer Video NEW
0 Listeners
GRACEcast Cancer 101 Video
0 Listeners